In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 931-938

  Whoon, Jong Kil ^a   Cerna, David ^a   Burgan, William E ^a,b   Beam, Katie ^a,b   Carter, Donna ^a,b   Steeg, Patricia S ^a   Tofilon, Philip J ^c   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL CYCLE G2 PHASE; CLONOGENIC ASSAY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA STRAND BREAKAGE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DACARBAZINE; DNA METHYLATION; DNA REPLICATION; GLIOBLASTOMA; HUMANS; MITOSIS; RADIATION-SENSITIZING AGENTS; TUMOR STEM CELL ASSAY;

EID: 38949170191     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1856     Document Type: Article

References (23)

1. Carter CA, Waud WR, Plowman J. Responses of human melanoma, ovarian, and colon tumor xenogragfts in nude mice to oral temozolomide. Proc Am Assoc Cancer Res 1994;35:297.
2. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
3. 6-alkylguainine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-29.
4. 6-alkylguainine-DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 2006;32:261-76.
5. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:989-96.
6. Hegi ME, Diserens A, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
7. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005;23:2372-77.
8. Van Rijn J, Heimans JJ, Van den Berg J, Van den Valk P, Slotman BJ. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000;47:779-84.
9. 6-methylguanine DNA methylatransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-76.
10. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006;12:4738-46.
11. Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8.
12. Tomasz K, Dobrovic W, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007;35:41-8.
13. 2-M checkpoints are induced by ionizing radiation. Mol Cell Biol 2002;22:1049-59.
14. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316-21.
15. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;8:2604-13.
16. 2 checkpoint abrogator. Cancer Res 2001;61:8211-17.
17. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce Histon H2AX phosphorylation on Serine 139. J Biol Chem 1998;273:5858-68.
18. Broker LE, Kruyt AE, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005;11:3155-62.
19. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997;8:92-7.
20. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)Idu-induced DNA double-starnd breaks with γ-H2AX antibody. Radiat Res 2002;158:486-92.
21. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-stand break repair in human cells exposed to very low X-ray doses. Proc Natl Acad Sci U S A 2003;100:5057-62.
22. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003;23:5706-15.
23. 1-phase cells. Radiat Res 2003;159:759-67.